Antenatal IFN was used in five pregnancies: two with CALR mutation and extreme thrombocytosis (white blood cell (WBC) above 2000 × 109/L), one with JAK2 mutation and prior thrombosis, and two with JAK2 mutation and prior second trimester pregnancy losses. This evidence concerns the gene JAK2 and thrombocytosis disease.